Acadia Pharmaceuticals
ACAD · Pharmaceuticals
$19.73
2.9%Amphstar Pharmaceuticals
AMPH · Pharmaceuticals
$25.14
3.5%The short version
- Acadia Pharmaceuticals is the larger business, with $1.1B of revenue in fiscal 2025 against $720M for Amphstar Pharmaceuticals.
- Acadia Pharmaceuticals grew revenue faster (11.9%, against −1.7%).
- Amphstar Pharmaceuticals kept more of each dollar of sales as operating profit (19.5% operating margin, against 9.8% operating margin).
- Amphstar Pharmaceuticals turned more of its sales into free cash flow (16.8% FCF margin, against 9.8% FCF margin).
- Investors pay more for each dollar of Amphstar Pharmaceuticals’s earnings: a P/E of 14.9x against 8.9x for Acadia Pharmaceuticals.
| Latest fiscal year | ACAD · FY25 | AMPH · FY25 |
|---|---|---|
| Size | ||
| Market cap | $3.4B | $1.1B |
| Revenue | $1.1B | $720M |
| Free cash flow | $105M | $121M |
| Net income | $391M | $98.1M |
| Growth | ||
| Revenue growth | 11.9% | −1.7% |
| 5-year growth | 19.4% | 15.5% |
| Share count change | 2.1% | −7.4% |
| Profitability | ||
| Gross margin | 91.7% | 49.5% |
| Operating margin | 9.8% | 19.5% |
| Net margin | 36.5% | 13.6% |
| FCF margin | 9.8% | 16.8% |
| Return on capital | — | 9.9% |
| Return on equity | 39.9% | 12.9% |
| Balance sheet | ||
| Net debt | — | $339M |
| Net debt / EBITDA | — | 1.7x |
| Dividends and buybacks | $0.0M | $75.6M |
| Valuation & quality | ||
| P/E | 8.9x | 14.9x |
| Piotroski F-score | — | 6 |
FY16
ACAD $17.3M
AMPH $255M
FY17
ACAD $125M
AMPH $240M
FY18
ACAD $224M
AMPH $295M
FY19
ACAD $339M
AMPH $322M
FY20
ACAD $442M
AMPH $350M
FY21
ACAD $484M
AMPH $438M
FY22
ACAD $517M
AMPH $499M
FY23
ACAD $726M
AMPH $644M
FY24
ACAD $958M
AMPH $732M
FY25
ACAD $1.1B
AMPH $720M
ACAD
AMPH
FY16
ACAD −1,574.1%
AMPH 6.0%
FY17
ACAD −234.1%
AMPH −0.5%
FY18
ACAD −110.6%
AMPH −2.9%
FY19
ACAD −72.7%
AMPH −0.0%
FY20
ACAD −64.9%
AMPH 3.1%
FY21
ACAD −35.2%
AMPH 16.0%
FY22
ACAD −43.2%
AMPH 21.5%
FY23
ACAD −10.1%
AMPH 30.6%
FY24
ACAD 24.1%
AMPH 28.1%
FY25
ACAD 9.8%
AMPH 19.5%
ACAD
AMPH
FY16
ACAD −$210M
AMPH $17.2M
FY17
ACAD −$219M
AMPH $4.1M
FY18
ACAD −$170M
AMPH −$8.6M
FY19
ACAD −$152M
AMPH $0.2M
FY20
ACAD −$144M
AMPH $23.4M
FY21
ACAD −$127M
AMPH $70.5M
FY22
ACAD −$114M
AMPH $65.2M
FY23
ACAD $16.7M
AMPH $145M
FY24
ACAD $157M
AMPH $172M
FY25
ACAD $105M
AMPH $121M
ACAD
AMPH
FY16
ACAD —
AMPH 3.7%
FY17
ACAD —
AMPH −0.4%
FY18
ACAD —
AMPH −2.1%
FY19
ACAD —
AMPH −0.0%
FY20
ACAD —
AMPH 1.4%
FY21
ACAD —
AMPH 13.4%
FY22
ACAD —
AMPH 20.9%
FY23
ACAD —
AMPH 22.6%
FY24
ACAD —
AMPH 16.4%
FY25
ACAD —
AMPH 9.9%
ACAD
AMPH
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.